loading
ANI Pharmaceuticals Inc stock is currently priced at $62.62, with a 24-hour trading volume of 88,445. It has seen a -0.98% decreased in the last 24 hours and a -5.16% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $63.46 pivot point. If it approaches the $62.35 support level, significant changes may occur.
Previous Close:
$63.24
Open:
$62.73
24h Volume:
88,445
Market Cap:
$1.31B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
-130.46
EPS:
-0.48
Net Cash Flow:
$100.45M
1W Performance:
-6.17%
1M Performance:
-5.16%
6M Performance:
+18.37%
1Y Performance:
+26.07%
1D Range:
Value
$62.05
$63.12
52W Range:
Value
$48.20
$70.81

ANI Pharmaceuticals Inc Stock (ANIP) Company Profile

Name
Name
ANI Pharmaceuticals Inc
Name
Phone
218-634-3500
Name
Address
210 Main Street West, Baudette, MN
Name
Employee
173
Name
Twitter
Name
Next Earnings Date
2024-05-21
Name
Latest SEC Filings
Name
ANIP's Discussions on Twitter

ANI Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-22-23 Reiterated H.C. Wainwright Buy
Mar-01-23 Initiated Guggenheim Buy
Sep-07-22 Initiated H.C. Wainwright Buy
Nov-02-21 Initiated Truist Buy
May-07-20 Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-12-19 Initiated Guggenheim Buy
May-10-19 Downgrade Raymond James Strong Buy → Outperform
Oct-16-17 Reiterated Canaccord Genuity Buy
Jul-31-17 Initiated Canaccord Genuity Buy
Feb-22-17 Downgrade ROTH Capital Buy → Neutral
Jun-23-16 Initiated Raymond James Strong Buy
May-24-16 Downgrade Standpoint Research Buy → Hold
Nov-13-15 Initiated Standpoint Research Buy
Sep-28-15 Upgrade ROTH Capital Neutral → Buy
Aug-05-15 Reiterated Oppenheimer Outperform
Aug-04-15 Reiterated ROTH Capital Neutral
Jul-31-15 Reiterated Oppenheimer Outperform
Jul-15-15 Reiterated ROTH Capital Neutral
Jun-23-15 Reiterated Oppenheimer Outperform
May-18-15 Reiterated ROTH Capital Neutral
May-06-15 Reiterated Oppenheimer Outperform
Apr-10-15 Downgrade ROTH Capital Buy → Neutral
Feb-26-15 Reiterated ROTH Capital Buy
Feb-18-15 Reiterated Oppenheimer Outperform
View All

ANI Pharmaceuticals Inc Stock (ANIP) Financials Data

ANI Pharmaceuticals Inc (ANIP) Revenue 2024

ANIP reported a revenue (TTM) of $486.82 million for the quarter ending December 31, 2023, a +53.87% rise year-over-year.
loading

ANI Pharmaceuticals Inc (ANIP) Net Income 2024

ANIP net income (TTM) was $18.78 million for the quarter ending December 31, 2023, a +139.21% increase year-over-year.
loading

ANI Pharmaceuticals Inc (ANIP) Cash Flow 2024

ANIP recorded a free cash flow (TTM) of $100.45 million for the quarter ending December 31, 2023, a +310.77% increase year-over-year.
loading

ANI Pharmaceuticals Inc (ANIP) Earnings per Share 2024

ANIP earnings per share (TTM) was $0.82 for the quarter ending December 31, 2023, a +126.97% growth year-over-year.
loading
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.
$67.77
price down icon 0.94%
$18.03
price down icon 0.44%
$55.48
price down icon 0.88%
drug_manufacturers_specialty_generic RDY
$71.85
price down icon 1.13%
$10.17
price down icon 2.12%
$135.45
price down icon 0.59%
Cap:     |  Volume (24h):